On May 29, June 1, and June 8, 2015, the first three subjects were enrolled in our ongoing study of MDMA-assisted psychotherapy for anxiety associated with life-threatening illness. Led by Principal Investigator Dr. Phil Wolfson in Marin, Calif., this study will treat 18 subjects suffering from anxiety related to a life-threatening disease that is either ongoing or in remission with a possibility of recurrence. “I feel absolutely honored to be meeting and working with our first three participants,” writes co-therapist Julane Andries, LMFT. “As they share their stories, and the physical and emotional pain they have endured, I am most impressed with their drive to seek help to be free from the fear, the anxiety, and depression that can come as one lives with life threatening illness.” On Sunday, May 24, the San Francisco Chronicle published a front-page article by journalist Don Lattin about increasing public understanding of psychedelic therapy research. “It’s a really interesting and a very powerful new approach,” Dr. Thomas Insel, director of the National Institute of Mental Health, told the Chronicle. “It’s not just taking MDMA. It’s taking it in the context of a treatment that involves improved insight and increased skills and using this in the broader context of psychotherapy.”